Abstract
The epidermal growth factor receptor (EGFR) is detected on many non- haematopoietic tissues and is frequently overexpressed in human tumors. With its ligand, TGF-α, it forms a well-defined autocrine growth loop. Several clinical approaches, using EGFR as a therapeutic target, are being investigated, particularly monoclonal antibodies combined with chemotherapy, and pharmacological inhibition of downstream components of the EGFR signaling pathway.
Original language | English (US) |
---|---|
Pages (from-to) | 133-141 |
Number of pages | 9 |
Journal | Cytokine and Growth Factor Reviews |
Volume | 7 |
Issue number | 2 |
DOIs | |
State | Published - Aug 1996 |
Keywords
- EGFR
- Human tumors
- Ligands
- Therapeutic targets
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Immunology and Allergy
- Immunology
- General Biochemistry, Genetics and Molecular Biology